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Importance: With the increasing use of antiangiogenic agents in the treatment of high-
grade gliomas, we are becoming increasingly aware of distinctive imaging findings seen in
a subset of patients treated with these agents. Of particular interest is the development of
regions of marked and persistent restricted diffusion. We describe a case with histopatho-
logic validation, confirming that this region of restricted diffusion represents necrosis and
not viable tumor.
Observations: We present a case report of a 52-year-old man with GBM treated with
temozolomide, radiation, and concurrent bevacizumab following gross total resection. The
patient underwent sequential MRI’s which included restriction-spectrum imaging (RSI),
an advanced diffusion-weighted imaging (DWI) technique, and MR perfusion. Following
surgery, the patient developed an area of restricted diffusion on RSI which became larger
and more confluent over the next several months. Marked signal intensity on RSI and
very low cerebral blood volume (CBV) on MR perfusion led us to favor bevacizumab-
related necrosis over recurrent tumor. Subsequent histopathologic evaluation confirmed
coagulative necrosis.
Conclusion and Relevance: Our report increases the number of pathologically proven
cases of bevacizumab-related necrosis in the literature from three to four. Furthermore,
our case demonstrates this phenomenon on RSI, which has been shown to have good
sensitivity to restricted diffusion.
Keywords: restriction-spectrum imaging, diffusion-weighted imaging, bevacizumab, glioblastoma multiforme,
necrosis
INTRODUCTION
We present a case of a 52-year-old man who first presented with a
generalized tonic-clonic seizure. Subsequent MRI revealed a ring
enhancing mass in the left frontal lobe. The patient underwent
gross total resection, and pathology was consistent with GBM.
Approximately 5 weeks later, the patient was started on stan-
dard combined chemotherapy and radiation (temozolomide at
75 mg/m2/day and involved-field radiation at a total dose of 60 Gy
in 2.0 Gy fractions over a 6-week period). Concurrently, the patient
was also started on bevacizumab as part of a clinical trial to assess
the efficacy of bevacizumab for newly diagnosed GBM. There-
after, the patient continued to receive adjuvant temozolomide and
bevacizumab for 9 months.
Sequential MRI’s were obtained during this time using
an advanced diffusion-weighted technique called Restriction-
Spectrum Imaging (RSI), which has been shown to pro-
vide improved conspicuity and delineation of high-grade pri-
mary and metastatic brain tumors compared with standard
diffusion-weighted imaging (DWI) (1). Approximately 6 months
following surgery, a small focal area of restricted diffusion
appeared on the RSI sequence adjacent to the resection cavity.
Over the next 18 months, this area of restricted diffusion became
significantly larger and more confluent, eventually crossing the
corpus callosum and extending into the contralateral frontal lobe
(Figure 1). During this time, the patient also had progressive cog-
nitive decline including increasing confusion, forgetfulness, and
abulia. Therefore the imaging findings were initially interpreted as
recurrent tumor and biopsy was considered.
However, on further inspection, it became clear that the degree
and homogeneity of the restricted diffusion seen in this case was
much greater than what is typically seen in high-grade glioma
(Figure 2A), with GBM’s usually demonstrating less intense and
more heterogeneous restricted diffusion. Furthermore, review of
the patient’s dynamic susceptibility contrast (DSC) MR perfusion
revealed that the cerebral blood volume (CBV) in the region of
the restricted diffusion lesion was remarkably low – lower than
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FIGURE 1 | Progression of findings on RSI over a 12-month period. Three coronal RSI images spanning a 12-month period following surgery and
chemoradiation depict an enlarging area of restricted diffusion which eventually crosses the corpus callosum and extends into the contralateral frontal lobe.
FIGURE 2 | (A,B) RSI and CBV maps in bevacizumab-related necrosis versus
GBM. (A) is a side-by-side comparison of the RSI signal seen in our patient
and the RSI signal seen in a typical GBM, with the two RSI images scaled
identically (i.e., same window and level). (B) is a side-by-side comparison of
the DSC MR perfusion-generated CBV map for this patient and the CBV map
for the same patient with GBM shown in (A) (with adjacent color scales).
that of the contralateral normal appearing white matter (NAWM).
In contradistinction, high-grade gliomas typically demonstrate
markedly elevated CBV (2, 3) (Figure 2B).
Given the findings of marked signal intensity on the RSI
sequence and very low CBV on DSC MR perfusion, it was
concluded that this large region of restricted diffusion likely
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FIGURE 3 | Correlation of the gross pathology with imaging. Coronal gross pathologic specimen as well as matched coronal FLAIR (fluid attenuated
inversion recovery), coronal T1 post-contrast, and coronal RSI sequences from the patient’s last available MRI for correlation.
represented bevacizumab-related necrosis, despite the fact that
it had enlarged over time and crossed the corpus callosum.
Therefore, biopsy was not pursued, and the patient continued to
be followed with sequential MRI’s. Approximately 2 years after
initial diagnosis, the patient expired, and underwent autopsy.
Gross pathologic evaluation demonstrated yellow, caseous mate-
rial in the left frontal lobe compatible with necrosis (Figure 3).
Histopathologic evaluation of this area revealed coagulative necro-
sis, gliosis, hyalinized blood vessels, and scattered atypical gemis-
tocytes (Figure 4A). Although it is unclear if these gemistocytes
represent tumor gemistocytes or reactive gemistocytic astrocytes,
the Ki-67 stain was completely negative (Figure 4B), indicat-
ing that these are non-proliferating cells. In short, there was no
evidence of proliferating, recurrent tumor at the time of autopsy.
BACKGROUND
Previous reports have described the development of regions of
marked and persistent restricted diffusion in a subset of patients
with malignant glioma during treatment with bevacizumab (4–
6). Histopathologic data from these regions reveal necrosis and
fibrotic,hyalinized blood vessels rather than viable tumor. Further-
more, these lesions have been correlated with improved outcomes
(5). However, based on standard MR imaging, differentiating these
lesions from areas of viable tumor, which are also associated with
restricted diffusion (7, 8), remains challenging.
DISCUSSION
Although the development of regions of marked and persistent
restricted diffusion has been described in a subset of malignant
glioma patients treated with bevacizumab (4–6), this is still a
fairly new phenomenon and has been pathologically proven in
only three patients, with the present case increasing this number
to four. Furthermore, these prior reports utilized standard DWI.
In the present case, we describe this same phenomenon using a
recently described advanced diffusion-weighted technique called
RSI (9). In previous studies, RSI has shown greater sensitivity to
restricted diffusion compared to standard DWI because it uti-
lizes multiple b-values and diffusion times to separate out the
spherically restricted water compartment from the hindered water
compartment (9). As demonstrated in Figure 1, the degree and
homogeneity of the RSI signal in this case is striking, facilitating
the differentiation of this area of bevacizumab-related necrosis
from recurrent tumor which demonstrates less intense and more
heterogeneous restricted diffusion (Figure 2A).
Furthermore, we demonstrate that by utilizing DSC MR per-
fusion, we can further increase our diagnostic certainty in dis-
criminating areas of bevacizumab-related necrosis from recur-
rent tumor. It is well known that MR perfusion of high-grade
glioma yields elevated CBV (2, 3). In the present case, the area of
bevacizumab-related necrosis demonstrated essentially no CBV,
corroborating similar findings in prior reports (5, 6) and further
differentiating this lesion from recurrent tumor.
The histopathologic findings in our case were very similar to
those described in the prior reports including coagulative necro-
sis, gliosis, and hyalinized blood vessels (Figure 4A). However,
our case also showed scattered atypical gemistocytes. Regardless
of whether these gemistocytes represented tumor gemistocytes or
reactive gemistocytic astrocytes, the Ki-67 stain was completely
negative (Figure 4B), indicating that these cells were inactive
non-proliferating cells and that no viable tumor was present.
Previous reports have proposed different explanations for the
etiology of these areas of marked and persistent restricted diffu-
sion. While one report has suggested that these lesions represent
exacerbation of radiation necrosis by bevacizumab (4), others
have suggested that these lesions result from bevacizumab-induced
chronic hypoxia (6). We favor the latter explanation as it is well
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FIGURE 4 | (A,B) Coagulative necrosis and negative Ki-67 stain. (A) Shows
two H&E stains from the grossly necrotic region; the first demonstrates
coagulative necrosis with a hyalinized fibrotic blood vessel in the center and
the second demonstrates scattered gemistocytes on a background of
edematous white matter. (B) is a Ki-67 stain of this region, which was
completely negative.
established that typical radiation necrosis actually demonstrates
decreased signal on DWI, due to facilitation of diffusion related
to liquefaction within the area of radiation necrosis (10). Fur-
ther investigation is needed with larger patient cohorts and more
histopathologic data, including immunohistochemistry, in order
to determine the actual pathophysiology of these lesions.
CONCLUDING REMARKS
In summary, we present a case of bevacizumab-related necro-
sis in a patient with GBM, emphasizing the distinctive appear-
ance of this entity on RSI which, together with perfusion
imaging, allowed us to differentiate this entity from recurrent
tumor.
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